SINGAPORE -- Nasdaq-listed BioNTech, which is testing a COVID-19 vaccine candidate, said Monday it has raised $250 million from Singapore state-owned investment company Temasek and other accredited investors in a private placement.
"We are pleased to welcome Temasek on board as a new shareholder. We believe their long-term investment approach, global presence, and deep experience in the biotechnology field are a good fit," Ugur Sahin, the German-based BioNTech's CEO and co-founder, said in a statement.
